In this study, we use the 22C3 Dako PharmDx assay, which is one of the first FDA-approved assays and widely used in many clinical laboratories, to evaluate three scoring methods for PD-L1 expression frequency and their associations with clinicopathologic factors, including stromal tumor infiltrating lymphocyte (TIL) levels, in breast cancer. Here, CD274 is linked to breast carcinoma.